Press release summary
EpiSign has launched METRIC 5-base, research-use-only software that applies its rare-disease episignature classification framework to DNA methylation data produced by sequencing platforms. The software supports Illumina 5-base, PacBio HiFi and Oxford Nanopore data and uses the same Version 6 framework the company applies to methylation microarrays.
EpiSign said the system provides automated analysis across more than 300 episignature disorders. Technical validation has been completed on the three supported sequencing platforms, while broader site-level validation is proceeding through the EpiSign Clinical Testing Network. Ambry Genetics has completed an initial evaluation using PacBio HiFi data, and Amsterdam UMC is evaluating an Oxford Nanopore workflow. The company said Greenwood Genetic Center is also positioned to assess the software in a clinical long-read sequencing program.
Why it matters for laboratories
Sequencing instruments can increasingly capture genetic variation and methylation information from the same dataset, but interpretation pipelines remain a barrier. A shared classifier could reduce the need for each laboratory to build hundreds of disease-specific models and reference sets. Adoption decisions should account for local validation, data quality, version control and reporting governance. The product is not cleared for clinical diagnostic use, and clinical implementation remains under evaluation.
Original source: EpiSign release distributed through CNW, Sept. 30, 2026.






Leave a Reply